Abstract
The medical indications for positive immunomodulation are becoming ever more widespread. In some situations, it is possible to use endogenous immunomodulators (IMs) or synthetics, but most of the experimentally tested IMs as well as those applied in clinical studies are of microbial origin. In the laboratories of the Institute of Pharmacology a new substance has been developed linking L-alanine-D isoglutamine residua of muramyl dipeptide with the antiviral l-amidoadamantan. This substance (adamantylamide dipeptide — AdDP) retains marked antiviral effects (Masihi et al. 1987) and shows positive IM properties as well (Masek et al. 1984). In our experiments in mice we tested the immunomodulatory properties of AdDP using several in vivo tests of cell mediated immunity. Selected were the regional graft-versus-host reaction (GVHR), regional host-versus-graft reaction (HVGR) and delayed type hypersensitivity (DTH) to SRBC (Sůla and Nouza 1984, Sůla et al 1988).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
